SPECIAL NOTICE
66 -- AcouSort AcouWash 2 System
- Notice Date
- 6/21/2022 8:19:12 AM
- Notice Type
- Special Notice
- NAICS
- 334516
— Analytical Laboratory Instrument Manufacturing
- Contracting Office
- NIH NCI ROCKVILLE MD 20852 USA
- ZIP Code
- 20852
- Response Due
- 7/5/2022 9:00:00 AM
- Description
- The National Cancer Institute (NCI), Center for Cancer Research (CCR), Molecular Imaging Branch (MIB) plans to procure an AccouSort AcouWash 2 System from AcouSort AB of Medicon Village, 223 81 Lund, Sweden on a sole source basis. This acquisition will be processed under FAR Part 12 � Acquisition for Commercial Items and will be made pursuant to the authority in FAR 13.106-1 (b)(1)(i) using simplified acquisition procedures for commercial acquisitions.� The response close date of this notice for this requirement is in accordance with FAR 5.203(a)(1). The North American Industry Classification System code is 334516 and the business size standard is 1,000 employees. The National Cancer Institute (NCI), Molecular Imaging Branch (MIB) has pioneered the use of acoustophoresis for immune cell radiolabeling with the goal of developing an automated tabletop cell radiolabeling system. This research began in 2017 with the purchase of the AcouWash 1 system from Acousort. The AcouWash, a device which uses acoustophoresis to purify cells and is an essential step in the immune cell radiolabeling process, was used for this work. The work to date has resulted in The Department of Health and Human Services filing a preliminary patent with the US Patent and Trademark Office. The next phase of the research will be to study the ability to use acoustophoresis to concentrate cells, a process traditionally performed using a centrifuge. AcouSort has developed a next generation acoustophoresis system which can concentrate cells as well as purify them. MIB�s research progress relies on the purchase of the AcouWash 2 from Acousort to study cell concentration in the cell radiolabeling process using acoustophoresis. The following product features/characteristics are required: Use acoustophoresis to purify and concentrate cell samples Acoustophoresis is required because the main question the research project is trying to resolve is whether acoustophoresis is a technology which can be used for cell labeling. Dual inlet, dual outlet separation microchip. Dual inlet and outlet are required for both purification and concentration of cells in solution Automatic internal precision flow regulation Precision flow regulation gives the AcouWash 2 the ability to concentrate cells, which is a key requirement to test acoustophoresis for cell radiolabeling. Temperature-controlled separation chip Temperature control is required because variations can affect activation of immune cells while they are being radiolabeled with the AcouWash 2. Live viewing for process monitoring Ultrasound frequency tuning relies on visual inspection of the flow of cells through the microchannel. Less than 3 min start-up time Short startup time allows for efficient throughput of cell radiolabeling. Cell wash of up to 10^7 cells/mL with > 90% recovery MIB will be testing cell concentrations on the order of 10^7 for the cell radiolabeling tests. Flowrates 20-500uL/min Variable flow rates are required to tune the radiolabeling sequences. Sample volumes 0.250-13mL High concentration and high volume are required for testing radiolabeling 10^8 cells. The Molecular Imaging Branch (MIB) requires an AcouWash 2 turnkey system including Acoustic wash chips, installation, and virtual training.� The AcouWash shall be used to partially automate the immune cell radiolabeling process by using acoustophoresis to concentrate and purify cells.� This will eliminate the centrifugation and pipetting steps which increase labeling efficiency by eliminating the manual steps.� To ensure the continuity of ongoing experiments and preliminary patent with the US Patent and Trademark Office, MIB must continue to use the AcouSort AcouWash platform. This notice is not a request for competitive quotation. However, if any interested party, especially small business believes it can meet the above requirement, it may submit a capability statement for the Government to consider. The response and any other information furnished must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can perform the requirement.� Responses must be received in the contracting office by 12:00 PM ET, on July 05, 2022.� All responses and questions must be via email to Miguel Diaz, Contracting Officer at miguel.diaz@nih.gov.� A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement.� In order to receive an award, contractors must be registered and have valid certification through SAM.GOV and have Representations and Certifications filled out. Reference: 75N91022Q00112 on all correspondence.
- Web Link
-
SAM.gov Permalink
(https://sam.gov/opp/f61853b3eece4007979dcf6294e1490b/view)
- Record
- SN06363373-F 20220623/220621230059 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |